Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types

The FDA has recently approved a high tumor mutational burden (TMB-high) biomarker, defined by ≥10 mutations/Mb, for the treatment of solid tumors with pembrolizumab, an immune checkpoint inhibitor (ICI) that targets PD1. However, recent studies have shown that this TMB-high biomarker is only able to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Neelam, Sinha, Sanju, Valero, Cristina, Schäffer, Alejandro A., Aldape, Kenneth, Litchfield, Kevin, Chan, Timothy A., Morris, Luc G.T., Ruppin, Eytan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Priority Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177633/
https://www.ncbi.nlm.nih.gov/pubmed/35385572
http://dx.doi.org/10.1158/0008-5472.CAN-21-2542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177633/
https://www.ncbi.nlm.nih.gov/pubmed/35385572
http://dx.doi.org/10.1158/0008-5472.CAN-21-2542

Ejemplares similares